OLMA

6.9552.73%
JO

Jason O’Byrne

CFO, Principal Financial Officer & Accounting Officer

Mr. Jason O'Byrne, MBA has been the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) since August 11, 2026. He was Executive VP & CFO of Vir Biotechnology, Inc. from October 2, 2024 until August 3, 2026. Mr. O'Byrne served as a Senior Vice President of Finance at Audentes Therapeutics, Inc since March 2020 until 2022. He served as Chief Financial Officer of Caribou Biosciences, Inc. since February 2021. He has global finance and operations experience across R&D, business development, manufacturing and commercial. Mr. O'Byrne is responsible for leading all aspects of the finance organization, leveraging his experience to prepare the team and systems for future commercial operations. Mr. O'Byrne joined Audentes in April 2019 as Vice President of Finance. He joined Audentes from Roche Pharmaceuticals, where he held positions of increasing responsibility, serving as Asia Pacific Head of Finance, based in Singapore. Prior to that, Mr. O'Byrne held finance leadership positions at Genentech and Roche across product development, research, supply chain and business development for years. Earlier in his career, Mr. O’Byrne spent many years at Genentech, Inc., a biotechnology company and its parent company the Roche Group, a global healthcare company, where he held finance leadership positions of increasing responsibility, including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy. Mr. O'Byrne was a controller with General Chemical and an engineer with General Motors. Mr. O'Byrne holds a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia and an M.B.A. in Finance from New York University.

Positions